A recently published narrative review in 'Current Clinical Pharmacology' illustrated the treatment options for drug-induced peripheral neuropathy (DIPN).

Peripheral neuropathy is a distressing ailment with various etiologies and specific medications have found to be associated with the development of DIPN. These include antimicrobials, chemotherapeutic agents, anticonvulsants, cardiovascular drugs, psychotropic etc. DIPN has shown to be developed in a dose-dependent fashion after the continued use of a neurotoxic agent in many cases. DIPN development should be suspected in patients who are receiving drug treatment and report the new onset symptoms of pain, paresthesia, or weakness. The motor and sensory nerve conduction studies may support the clinical diagnosis in patients in whom a history of DIPN is doubted. The occurrence of DIPN becomes even more prevalent in patients with risk factors such as diabetes, pre-existing neuropathy or genetically predisposing diseases. Often, DIPN is challenging to treat, but medications like duloxetine and gabapentin have been proved to decrease the neuropathic pain. The advanced techniques of neuromodulation are quite promising but more randomised and controlled studies are required in future to confirm the efficacy of them.